Children’s National Hospital announces that it has entered into a licensing agreement with MGeneRx Inc. for its patented pediatric medical device technology using objective digital biometric analysis software for the early and non-invasive screening of dysmorphic genetic diseases. The technology was developed by Children’s National to provide a more advanced diagnostic tool for regions of the world with limited access to geneticists or genetic testing. MGeneRx is a spinoff from BreakThrough BioAssets LLC, a life sciences technology operating company focused on accelerating and commercializing new innovations, such as this technology, with an emphasis on positive social impact.
Children’s National Hospital announces licensing agreement with MGeneRx Inc. for proprietary biometric analysis technology
